Similar one-year primary patency rates of common femoral artery angioplasty alone when performed utilizing drug-coated versus noncoated balloons for the treatment of peripheral artery disease

Although surgical endarterectomy is the first-line therapy for common femoral artery (CFA) lesions in patients with peripheral artery disease (PAD),1 endovascular therapy (EVT) has been conditionally chosen in clinical practice. However, the clinical outcomes of drug-coated balloon (DCB) versus noncoated balloon (NCB) treatment of CFA lesions have not been systematically studied. Therefore, we conducted the CELERY (Common fEmoraL artERY intervention) study. A total of 224 consecutive patients with symptomatic PAD underwent primarily EVT for CFA lesions between April 2016 and June 2019 at four cardiovascular centers in Japan. After excluding the patients treated with stents (18 patients), the remaining 206 patients were analyzed. The current study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of Kansai Rosai Hospital (reference number 20D031g). The primary outcome measure was the 1-year primary patency rate. A loss of primary patency was defined as a peak systolic velocity ratio > 2.4 according to duplex ultrasound, or the recurrence of stenosis ⩾ 50% of the arterial diameter, as determined by angiography. In the patient who underwent common femoral surgical endarterectomy for restenotic lesions after failed DCB angioplasty, we conducted histological evaluation of the removed plaque to assess the vascular response of DCB for neointimal inhibition. Data are presented as the mean ± SD for continuous variables and as percentages for discrete variables. Cumulative primary patency rate was estimated using the Kaplan–Meier method. Independent associations were explored using a multivariate Cox proportional hazards model. Statistical significance was considered at p < 0.05. Statistical analyses were performed using SPSS software version 24.0 J (IBM Corp., Armonk, NY, USA). Baseline characteristics are summarized in the online Supplemental table. The 1-year primary patency rate was 57.5% (48.1% to 66.9%) in the DCB group and 63.3% (59.4% to 67.2%) in the NCB group, with no significant intergroup difference (p = 0.59; Figure 1A). In Figures 1B and 1C, a representative case subsequently undergoing surgical endarterectomy after failed DCB angioplasty shows that remarkable neointimal proliferation (red asterisk) on the luminal side of a calcified plaque (black arrow) with a crack (red arrow) was histopathologically evaluated. Multivariate analysis revealed that bilateral calcification, presence of a calcified nodule, and the Medina 1-1-1 bifurcation lesions were significantly associated with loss of primary patency; the adjusted hazard ratios [95% CIs] were 1.77 [1.05–2.98] (p = 0.032), 2.99 [1.56–5.70] (p = 0.001), and 1.94 [1.13–3.34] (p = 0.016), respectively. The current study revealed that 1-year primary patency was not significantly different between DCB and NCB in real-world CFA practice. Although the results of the TECCO (Endovascular Versus Open Repair of the Common Femoral Artery) trial, a sole randomized trial comparing surgical endarterectomy with stenting for CFA, reported comparable primary patency rates in both treatments,2 a previous study revealed DCB angioplasty showed a significantly lower primary patency rate compared with endarterectomy (75.0% vs 96.7% at 1 year, respectively).3 Potential reasons for the ineffectiveness of DCB for CFA lesions may include (1) early recoil of the lesions due Similar one-year primary patency rates of common femoral artery angioplasty alone when performed utilizing drug-coated versus noncoated balloons for the treatment of peripheral artery disease